Holen Sie sich die Stockscreener-App
7.45
1.36%
0.10
Handel nachbörslich:
7.59
0.14
+1.88%
Schlusskurs vom Vortag:
$7.35
Offen:
$7.44
24-Stunden-Volumen:
484.46K
Relative Volume:
1.33
Marktkapitalisierung:
$379.14M
Einnahmen:
$228.37M
Nettoeinkommen (Verlust:
$31.11M
KGV:
12.20
EPS:
0.6108
Netto-Cashflow:
$41.73M
1W Leistung:
-0.40%
1M Leistung:
+8.13%
6M Leistung:
+52.04%
1J Leistung:
+150.00%
1-Tages-Spanne:
$7.395
$7.6999
1-Wochen-Bereich:
$7.11
$7.70
52-Wochen-Spanne:
$2.85
$7.8983
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
7.45 | 374.05M | 228.37M | 31.11M | 41.73M | 0.6108 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Six new Puma hires get stock awards covering 59,750 shares - Stock Titan
MSN Money - MSN
Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday - MarketBeat
PBYI Stock Price, Quote & Chart | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Puma Biotechnology | 10-Q: Q2 2025 Earnings Report - Moomoo
CEO warrant extension and pay vote at Puma Biotechnology (NASDAQ: PBYI) meeting - Stock Titan
[ARS] PUMA BIOTECHNOLOGY, INC. SEC Filing - Stock Titan
Puma Biotechnology (PBYI) Stock Price Alert (Technical Strength) 2026-04-27Investment Picks - Newser
Puma Biotechnology stock declines more than 9% in a month: Here's why - MSN
Press Release: Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results - 富途牛牛
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results - BioSpace
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Ritholtz Wealth Management Boosts Stake in Puma Biotechnology - National Today
Puma Biotechnology, Inc. $PBYI Shares Acquired by Ritholtz Wealth Management - MarketBeat
Is Puma Biotechnology (PBYI) Stock Attractive Now | Price at $7.72, Down 0.96%Sentiment Analysis - Cổng thông tin điện tử tỉnh Lào Cai
What Do Analysts Think About Puma Biotechnology (PBYI)? - MSN
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Puma Biotechnology Stock Surges Past 200-Day Average - National Today
Puma Biotechnology (NASDAQ: PBYI) seeks votes to extend CEO warrant, elect directors - Stock Titan
Can Puma Biotechnology Inc sustain its profitabilityWeekly Stock Analysis & Real-Time Market Trend Scan - baoquankhu1.vn
PBYI PE Ratio & Valuation, Is PBYI Overvalued - Intellectia AI
Investor Mood: Is Puma Biotechnology Inc undervalued by DCF analysisWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
PBYI Stock Analysis: Puma Biotechnology Inc holds 6.9 level after 2.07 pct gain - Cổng thông tin điện tử tỉnh Tây Ninh
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Pharma News: Is Puma Biotechnology Inc a momentum stockAnalyst Downgrade & Capital Efficiency Focused Ideas - baoquankhu1.vn
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Recap Report: What is Puma Biotechnology Incs 5 year growth outlook2026 Technicals & Low Risk Growth Stock Ideas - baoquankhu1.vn
Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially - Investing.com
Earnings call transcript: Puma Biotechnology Inc. reports strong Q4 2025 results - in.investing.com
Vanguard disaggregates holdings; Puma Biotechnology (PBYI) shows 0 shares reported - stocktitan.net
Forecast Cut: Is Puma Biotechnology Inc a momentum stockPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
Rate Hike: Can Puma Biotechnology Inc be the next market leaderPortfolio Update Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy - MarketBeat
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):